EURURO Vol. 72 No. 5

CONTENTS

e u r o p e a n u r o l o g y , vo l . 7 2 , n o . 5 , No v emb e r 2 0 1 7

e113

The Platinum Hall of Fame http://dx.doi.org/10.1016/j.eururo.2017.09.003

657

The Search for the Missing Heritability of Prostate Cancer

P.C. Walsh

Scientists and clinicians at Johns Hopkins have been working since 1987 to uncover

the genetic pathogenesis of prostate cancer. A patient query about the hereditary

nature of the disease led to data collection on family history, followed by

segregation and linkage analyses. Collaborative investigations using next-

generation sequencing to identify genetic variants associated with prostate cancer

risk have revealed the significance of

HOXB13, BRCA 1/2

, and DNA repair mutations.

660

Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis

B. Bhindi, I. Frank, R.J. Mason, R.F. Tarrell, P. Thapa, J.C. Cheville, B.A. Costello, L.C. Pagliaro,

R.J. Karnes, R.H. Thompson, M.K. Tollefson, S.A. Boorjian

Patients who achieve a complete response after neoadjuvant chemotherapy have

excellent survival outcomes. However, patients with residual disease at cystectomy

after neoadjuvant chemotherapy have a worse prognosis compared to pathological

stage-matched patients who underwent cystectomy alone.

665

A Prostate Cancer “ Nimbosus ”: Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies

M.L.K. Chua, W. Lo, M. Pintilie, J. Murgic, E. Lalonde, V. Bhandari, O. Mahamud, A. Gopalan,

C.F. Kweldam, G.J.L.H. van Leenders, E.I. Verhoef, A.M. Hoogland, J. Livingstone, A. Berlin,

A. Dal Pra, A. Meng, J. Zhang, M. Orain, V. Picard, H. Hovington, A. Bergeron, L. Lacombe,

Y. Fradet, B. Têtu, V.E. Reuter, N. Fleshner, M. Fraser, P.C. Boutros, T.H. van der Kwast, R.G. Bristow

We posit a prostate cancer “

nimbosus

” that is hallmarked by the constellation of

genomic instability,

SChLAP1

dysregulation, hypoxia, and intraductal-cribriform

subpathologies. Patients harboring these prostate cancers should be closelymonitored

and are recommended intensified treatment against an increased risk of metastases.

675

Convergence of Genomic Instability and SChLAP1 : Weathering the Stormof Intraductal Carcinoma of the Prostate

D.E. Spratt

677

A Pragmatic Randomized Controlled Trial Examining the Impact of the Retzius- sparing Approach on Early Urinary Continence Recovery After Robot-assisted Radical Prostatectomy

D. Dalela, W. Jeong, M.-A. Prasad, A. Sood, F. Abdollah, M. Diaz, P. Karabon, J. Sammon, M. Jamil,

B. Baize, A. Simone, M. Menon

We conducted a randomized controlled trial comparing the short-term ( 3mo) urinary

outcomes of patients undergoing posterior (Retzius-sparing) approach of robot-assisted

radical prostatectomy (RARP) with those undergoing the standard (anterior) approach.

We noted that patients in the posterior RARP armhad superior continence outcomes at

1 wk, 2 wk, 1mo, and 3mo, along with favorable urinary function-related bother scores.

686

Will Retzius-sparing Prostatectomy Be the Future of Prostate Cancer Surgery?

A. Galfano, S. Secco, A.M. Bocciardi

PlatinumOpinion

Brief Correspondence

Platinum Priorities

Original Articles and Review

Articles together with the Full

Length Editorials

Prostate Cancer